NasdaqHealth CareHealth Care SuppliesS&P SmallCap 600
$11.76
+0.08 (+0.68%)
Close of Nov 06, 2026 · end-of-day data
NEOG 8-K filings in 2026
Every material Form 8-K Neogen filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Neogen said it expects regulatory review of its planned sale of its global Genomics business to Zoetis to conclude in early 2027. The deal, first announced March 2, 2026, remains subject to customary closing conditions and regulatory approvals, and Zoetis has offered to divest certain Australian assets to help clear the review. The filing gives no purchase price or financial impact, so shareholders face a longer timeline before the transaction can close.
Neogen agreed on March 2, 2026 to sell its global Genomics business to Zoetis Inc.
The Australian Competition and Consumer Commission and New Zealand Commerce Commission are continuing reviews of the transaction.
Zoetis has offered to divest certain assets in Australia to assist the clearance process.
Neogen expects regulatory review to conclude in early 2027.
Neogen reported first-quarter fiscal 2027 revenue of $222.8 million, up 6.5% from a year earlier, and raised its fiscal 2027 revenue and Adjusted EBITDA guidance. The company still posted a GAAP net loss of $11.9 million, compared with net income of $36.3 million a year earlier, when a $76.4 million gain on the sale of a business boosted results.
Revenue of $222.8 million vs. $209.2 million a year earlier; core revenue growth of 8.1%
Net loss of $11.9 million, or $(0.05) per diluted share, vs. net income of $36.3 million, or $0.17, a year earlier; Adjusted EPS was $0.08 vs. $0.04
Fiscal 2027 revenue guidance raised to $885 million to $890 million from $880 million to $885 million; Adjusted EBITDA guidance raised to $181 million to $183 million from $180 million to $182 million
Pending sale of the Genomics business to Zoetis Inc. is expected to conclude regulatory reviews by the end of December 2026
Neogen Corporation disclosed that director Thierry Bernard resigned from its Board of Directors on August 3, 2026. The filing does not state a reason for the resignation or name a replacement.
Thierry Bernard resigned from the Neogen Board of Directors on August 3, 2026.
The filing gives no reason for the resignation.
No successor director or board appointment is named in this filing.
Neogen reported fiscal fourth-quarter 2026 revenue of $225.3 million, down 0.1% from a year earlier, with core revenue growth of 4.3%. The net loss narrowed sharply from $612.2 million a year earlier, which included a $597.9 million goodwill impairment, and the company gave fiscal 2027 revenue guidance of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million.
Q4 fiscal 2026 revenue $225.3 million vs $225.5 million a year earlier; full fiscal year revenue $870.4 million, down 2.7%
Q4 net loss $11.3 million, or $(0.05) per diluted share, vs $(2.82) a year earlier; adjusted EPS $0.09 vs $0.05
Q4 adjusted EBITDA $45.4 million, margin 20.2%, vs $40.6 million and 18.0% a year earlier
FY27 guidance: revenue $880 million to $885 million and adjusted EBITDA about $180 million to $182 million, excluding the pending Genomics sale to Zoetis Inc. details to be updated later
Neogen reported fiscal third-quarter 2026 revenue of $211.2 million, down 4.4% from a year earlier, and a net loss of $17.0 million, or $(0.08) per share, compared with a $10.9 million loss a year earlier. The company raised its fiscal 2026 revenue guidance to $857 million to $860 million, kept Adjusted EBITDA guidance at about $175 million, and announced a $160.0 million sale of its Genomics business to Zoetis.
Q3 revenue was $211.2 million, down from $221.0 million; Animal Safety revenue fell 20.1% on third-party supplier issues
Net loss was $17.0 million, or $(0.08) per diluted share; Adjusted EPS was $0.09 versus $0.10 a year earlier
FY26 revenue guidance raised to $857 million to $860 million from $845 million to $855 million; Adjusted EBITDA guidance held at about $175 million
Genomics business to be sold to Zoetis Inc. for $160.0 million, expected to close by the end of fiscal 2Q27
Neogen Corporation disclosed that Amy Rocklin, its Chief Legal and Administrative Officer, will leave the company effective March 31, 2026. The filing does not state a reason for the departure or name a successor.
Amy Rocklin, Chief Legal and Administrative Officer, departs effective March 31, 2026
Announcement made March 30, 2026
Filing does not name a replacement or give a reason for the departure
Neogen reported fiscal 2026 second-quarter revenue of $224.7 million, down 2.8% from a year earlier, though core revenue rose 2.9%. The net loss narrowed to $15.9 million from $456.3 million a year earlier, which included a goodwill impairment, but adjusted net income fell to $22.6 million from $24.4 million. The company raised its fiscal 2026 revenue outlook to $845 million to $855 million and its adjusted EBITDA outlook to about $175 million.
Revenue was $224.7 million, down 2.8% from $231.3 million; core revenue rose 2.9%, while divestitures and discontinued product lines reduced revenue by 6.6%.
Net loss was $15.9 million, or $(0.07) per diluted share, versus a $456.3 million loss a year earlier that included a $461.4 million goodwill impairment.
Adjusted EBITDA was $48.7 million, down from $51.4 million; gross margin was 47.5%, down from 49.0%, citing tariff costs, inventory write-offs and product mix.
For fiscal 2026, revenue is now expected at $845 million to $855 million and adjusted EBITDA at approximately $175 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Neogen filing is on SEC EDGAR ↗. 8-K briefs of other companies →